Risk of infections in multiple myeloma. A population-based study on 8672 multiple myeloma patients diagnosed 2008-2021 from the Swedish Myeloma Registry

Gastrointestinal Cancer

Panacreatic cancer risk after benign gallbladder disease: A Swedish population-based cohort study

Eur J Cancer

Radkiewicz C, Ludvigsson JF, Sparrelid E, Emilsson L

doi: 10.1016/j.ejca.2024.115140

Multiple Myeloma (MM)

Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry

Blood Cancer J

Ailawadhi S, Lee HC, Omel J, Toomey K, Hardin JW, Gasparetto CJ, Jagannath S, Rifkin RM, Durie BGM, Narang M, Terebelo HR, Joshi P, Jou YM, Mouro J, Yu E, Abonour R

doi: 10.1038/s41408-024-01177-6

Multiple Myeloma (MM)

French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry

Br J Haematol

Ferment B, Lambert J, Caillot D, Lafon I, Karlin L, Lazareth A, Touzeau C, Leleu X, Moya N, Harel S, Perrot A, Bories P, Vincent L, Lamure S, Mohty M, Malard F, Manier S, Yakoub-Agha I, Schiano De Colella JM, Brisou G, Talbot A, Decaux O, Houot R, Le Gouill S, Bigot N, Facon T, Corre J, Moreau P, Arnulf B, Intergroupe Francophone du Myélome

doi: 10.1111/bjh.19505

Multiple Myeloma (MM)

Response adaptive salvage treatment with daratumumab-lenalidomide-dexamethasone for newly diagnosed transplant-eligible multiple myeloma patients failing front-line bortezomib-based induction therapy-ALLG MM21

Br J Haematol

Lim S, Reynolds J, Quach H, Hutchinson A, Kerridge I, Janowski W, Bergin K, Spencer A

doi: 10.1111/bjh.19578

Multiple Myeloma (MM)

Treatment adherence and effectiveness in patients treated with carfilzomib-based therapy combinations for relapsed/refractory multiple myeloma in Germany: interim results from the non-interventional CARO study

Leuk Lymphoma

Knauf W, Uhlig J, von der Heyde E, Losem C, Ammon A, Nusch A, Schlag R, Schulz H, Janssen J, Welslau M, Wilop S, Vannier C, Siebenbach HU, Serrer L, Schuch A, Woerner SM, Engelhardt M, Potthoff K

doi: 10.1080/10428194.2024.2436034

Multiple Myeloma (MM)

Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database

Blood Cancer J

Rajkumar SV, Mateos MV, Schaeffer M, Lin X, Bathija S, Gupta-Werner N, Lam A, Carson R, Dennis R, Kaila S, Matt K, Duran J, Lonial S

doi: 10.1038/s41408-024-01170-z

ASH 2024

Multiple Myeloma (MM)

EMN15/HOVON147: Adding carfilzomib to Rd significantly improves MRD negativity rates in patients with high-risk smoldering multiple myeloma

Multiple Myeloma (MM)

Real-world treatment patterns and outcomes for patients with multiple myeloma in Denmark, Finland and Sweden: An analysis using linked Nordic registries

Eur J Cancer

Abildgaard N, Anttila P, Waage A, Rubin KH, Ørstavik S, Bent-Ennakhil N, Gavini F, Ma Y, Freilich J, Hansson M

doi: 10.1016/j.ejca.2024.113921

Genitourinary Cancer

Prognostic factors for relapse in patients with clinical stage I testicular non-seminoma: A nationwide, population-based cohort study

Eur J Cancer

Wagner T, Toft BG, Lauritsen J, Bandak M, Christensen IJ, Engvad B, Kreiberg M, Agerbæk M, Dysager L, Carus A, Rosenvilde JJ, Berney D, Daugaard G

doi: 10.1016/j.ejca.2024.114025

Related content

Panacreatic cancer risk after benign gallbladder disease: A Swedish population-based cohort study

Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry

French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry

Response adaptive salvage treatment with daratumumab-lenalidomide-dexamethasone for newly diagnosed transplant-eligible multiple myeloma patients failing front-line bortezomib-based induction therapy-ALLG MM21

Treatment adherence and effectiveness in patients treated with carfilzomib-based therapy combinations for relapsed/refractory multiple myeloma in Germany: interim results from the non-interventional CARO study

Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database

EMN15/HOVON147: Adding carfilzomib to Rd significantly improves MRD negativity rates in patients with high-risk smoldering multiple myeloma

Real-world treatment patterns and outcomes for patients with multiple myeloma in Denmark, Finland and Sweden: An analysis using linked Nordic registries

Prognostic factors for relapse in patients with clinical stage I testicular non-seminoma: A nationwide, population-based cohort study